Reported 2 days ago
Novartis has announced its acquisition of Regulus Therapeutics for $800 million, gaining access to the drug farabursen, which targets kidney disease. This agreement includes a premium payment to shareholders and further conditional payments tied to regulatory milestones. Regulus, founded in 2007, faced challenges but has now entered clinical stages with farabursen, aimed at treating autosomal dominant polycystic kidney disease (ADPKD), an area of growing interest for Novartis as it expands its renal treatment portfolio.
Source: YAHOO